Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Ipilimumab + Nivolumab & Renal cell carcinoma (RCC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Regulatory status

In the context of Ipilimumab + Nivolumab & Renal cell carcinoma (RCC), ipilimumab + nivolumab is approved for first‑line, intermediate‑ or poor‑risk advanced Renal cell carcinoma (RCC) by both the FDA and the EMA, with the same dosing rationale and patient‑selection criteria (1, 3, 4)

Clinical data:

Although data are encouraging, less than 50% of pts will exhibit partial or complete response with Ipilimumab + Nivolumab, and approximately 20% of pts will progress through this regimen (…

References (Sources)

Clinical Review on the Management of Metastatic Renal Cell Carcinoma
Tran & Ornstein 2022 JCO Oncol Pract 18: 187-196
Review
Ipilimumab in combination with nivolumab for the treatment of renal cell carcinoma
Gao & McDermott 2018 Expert Opin Biol Ther 18(9): 947-957
Review
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies
Salama & Moschos 2017 Ann. Oncol. 28: 57–74
Review
NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Adler et al. 2019 Lancet Oncology 20: 904-905
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
Vano et al. 2022 The Lancet Oncology 23: 612-624
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
McKay et al. 2020 JCO 38: 4240–4248
Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
Cella et al. 2019 Lancet Oncology 20: 297-310

AI Chat

7/1/2026

Chat with our artificial intelligence:

Links

https://actionkidneycancer.org/european-commission-approves-nivolumab-plus-ipilimumab-combination-for-first-line-advanced-rcc/
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-combination-intermediate-or-poor-risk-advanced-renal-cell)